Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Carrie Mihordin (NPI 1548458672)

Field	Value
Entity Type	Individual
Organization	Carrie Mihordin
Address	5701 W 119th St
City	Overland Park
State	KS
ZIP	66209
Taxonomy	Rheumatology Physician
NPI Enumerated	October 15, 2007

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider is effectively single‑payer at the public program level: total Medicare revenue is $1.5M and there is no Medicaid billing on file, so Medicaid does not contribute to this profile and the practice’s public‑payer exposure is concentrated in Medicare. Analysts should treat Medicaid network presence as absent rather than low.

Revenue is highly concentrated in a small set of biologic infusion/administration codes: the precomputed top 3 Medicare codes account for 63.9% of the provider’s total Medicare revenue, driven by J0129 ($383.9K, 25.7%), J3262 ($304K, 20.3%), and J0717 ($267.4K, 17.9%). This concentration indicates the practice’s economics are dependent on high‑cost injectable biologics rather than office E/M visits.

The CPT/HCPCS mix is consistent with a rheumatology practice operating an infusion/administration service line: leading codes are J0129 (abatacept), J3262 (tocilizumab), J0717 (certolizumab pegol), and J1602 (golimumab), plus infliximab (J1745). These are physician‑administered biologic therapies commonly used in rheumatologic care, indicating on‑site drug administration and infusion capability is a material part of how the provider generates revenue.

Despite the high dollar share of biologics, the provider’s national competitive standing on those drugs is modest rather than dominant. J0129 ranks #403 of 1221 (67th percentile; typical, unremarkable volume for this code), J3262 ranks #175 of 618 (72th percentile; typical, unremarkable volume for this code), and J0717 ranks #271 of 848 (68th percentile; typical, unremarkable volume for this code), which together point to above‑median but not top‑tier volume nationally.

Other infusion and chemotherapy administration codes appear in the mix at non‑trivial rank percentiles even though their revenue shares are small, suggesting operational capability beyond routine office visits. For example, 96413 accounts for $45.4K (3.0% of Medicare revenue) and ranks #789 of 7514 (89th percentile; typical, unremarkable volume for this code), and 96401 accounts for $20.4K (1.4%) and ranks #403 of 3868 (90th percentile; typical, unremarkable volume for this code), indicating the practice bills for antineoplastic/infusion administration at higher percentile ranks despite limited dollars.

Office evaluation-and-management visits and standard injection codes contribute relatively little to revenue compared with biologics: 99214 generates $38.8K (2.6%) and 99213 generates $9.3K (0.6%), while smaller injectable steroid codes such as J3301 and J2930 appear at low rank percentiles and negligible revenue. This pattern reinforces that the business model centers on high‑priced biologic drug administration rather than volume of routine office visits.

Several codes sit near the lower end of national percentile distributions, reflecting specific low‑volume billing lines that could be ancillary to the core infusion practice. For example, 96375 reports $297 (0.0%) and ranks #4797 of 5191 (7th percentile; typical, unremarkable volume for this code), J3301 reports $90 (0.0%) and ranks #25480 of 38702 (34th percentile; typical, unremarkable volume for this code), and J2930 reports $56 (0.0%) and ranks #2105 of 2459 (10th percentile; typical, unremarkable volume for this code).

The provider’s enrollment/tenure is long‑standing: NPI enumerated on 2007-10-15 (~19 years ago), indicating an established presence in the market which may support continued payer relationships and negotiated arrangements for infusion services. This tenure combined with a biologic‑heavy revenue mix suggests a stable specialist practice focused on administered therapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

14 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	11,290	$30	$383.9K
J3262	Injection, tocilizumab, 1 mg	60,800	$10	$304K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	66,840	$1	$267.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	21,100	$10	$211K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,760	$30	$149.8K
J0897	Injection, denosumab, 1 mg	3,240	$20	$61.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	470	$100	$45.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	410	$100	$38.8K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	380	$50	$20.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	140	$70	$9.3K

Showing 1–10 of 14

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Carrie Mihordin — 0 of 14 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

14 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	4	20	8,000	$30	$291.5K
J3262	6	10	60,820	$1	$243K
J0717	3	10	51,600	$1	$200.4K
J1602	4	20	14,360	$10	$167.7K
J1745	6	20	3,110	$30	$96.9K
J0897	61	180	2,160	$20	$81.5K
96413	20	80	80	$90	$26.3K
99214	718	4,310	120	$70	$16.4K
96401	3	30	180	$50	$9K
99213	1,543	4,330	90	$50	$8.7K

Showing 1–10 of 14

Related Providers

Other providers that share a Tax Identification Number (TIN) with Carrie Mihordin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sarah Vodopest	KS	Rheumatology Physician	$1.5M	$0
Jonathan Amos	KS	Rheumatology Physician	$951.5K	$0
Robyn Moran	KS	Rheumatology Physician	$859.1K	$0
Jaymi Anson	KS	Family Nurse Practitioner	$120.2K	$0

Nearby Providers

Other providers in the same ZIP code as Carrie Mihordin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lamar Court Assisted Living	KS	Assisted Living Facility	$0	$3.4M
Mid-america Surgery Institute LLC	KS	Ambulatory Surgical Clinic/Center	$1.4M	$0
Thomas Hocker	KS	MOHS-Micrographic Surgery Physician	$1.1M	$0
Midwest Heart & Vascular Specialists, LLC	KS	Cardiovascular Disease Physician	$0	$1M
Playabilities For Sensational Kids, LLC	KS	Pediatric Occupational Therapist	$0	$790.8K
Ads Healthcare LLC	KS	Ambulatory Surgical Clinic/Center	$734K	$0
Michael Sokol	KS	Endocrinology, Diabetes & Metabolism Physician	$368.5K	$0
Cameron Ledford	KS	Orthopaedic Surgery Physician	$304.4K	$0
Daniel Kloster	KS	Interventional Pain Medicine Physician	$291.3K	$0
Rachel Sosland	KS	Cardiovascular Disease Physician	$248K	$0

Carrie Mihordin — Billing Profile & Reimbursement Data

Sign up for Carrie Mihordin — Billing Profile & Reimbursement Data policy alerts

Carrie Mihordin — Billing Profile & Reimbursement Data

Sign up for Carrie Mihordin — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References